Imbruvica (ibrutinib)

pCPA File Number: 22489

Negotiation Status:

Active Negotiation

Indication(s):

In combination with venetoclax for the treatment of adult patients with previously untreated chronic lymphocytic leukemia (CLL), including those with 17p deletion.

Sponsor/Manufacturer:

Janssen Inc.

CDA-AMC Project Number:

PC0317-000

pCPA Engagement Letter Issued:

2024-10-03

Negotiation Process Concluded:

Not Applicable